Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?
Marler
John R
JR
National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892-9520, USA. marlerj@ninds.nih.gov
D006801:Humans; D010960:Plasminogen Activators / Q000627:therapeutic use*; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome
D010960:Plasminogen Activators